Continuous infusion of recombinant factor VIIa in hemophilic patients with inhibitors: safety, monitoring, and cost effectiveness.
about
Rare case of acquired haemophilia and lupus anticoagulant.Continuous infusion of coagulation factors.The pharmacokinetics of clotting factor therapy.Control of bleeding in patients with haemophilia A with inhibitors: a systematic review.Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors.Optimal use of recombinant factor VIIa in the control of bleeding episodes in hemophilic patients.A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven).A web-based registry of inherited bleeding disorders in the region of Emilia-Romagna: results at three and a half years.Major orthopaedic surgeries for haemophilia with inhibitors using rFVIIa.A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa aCoexistence of lupus anticoagulant and acquired haemophilia in a patient with monoclonal gammopathy of unknown significance.Continuous infusion of coagulation factor concentrates during intensive treatment.Thrombin-activable factor X re-establishes an intrinsic amplification in tenase-deficient plasmas.Use of recombinant factor VIIa in infants with severe coagulopathy.
P2860
Q33969541-5EA336B5-5570-44EA-93BF-6466E37847E8Q34636862-82D7B803-E237-4612-BD0C-652F47CA7E56Q35163599-C352DA16-9D5D-4543-BF3E-6AA3EB6C6530Q35163644-9AA68E80-A107-4030-83A2-3E62A8DE542DQ35771690-1F881AAE-F779-477B-B68B-DFECE04A0BAFQ37778292-98C0DFC3-56B2-4585-B538-8831D7B4F2FDQ39392420-7BF9AEEF-0E6C-4777-9989-463324C151E9Q42639765-84E94032-F577-4489-BACD-7965F18A5A13Q45855177-1E1FF48D-1D8A-4FDB-8114-199ACDCA4B7CQ45870380-458A1217-4CEF-4D22-BC0B-590D905ACD84Q45870792-DD7C6DC8-7CFA-46C4-A7A3-5E5155FA24E2Q45871553-FA64DBA0-B3CF-4327-83E4-DDB0172714AEQ45887421-010C347A-C25E-418D-8C8F-964F1CD87314Q47677743-6E39E5D0-36F1-43D0-B123-1E3CD3FB2FB8
P2860
Continuous infusion of recombinant factor VIIa in hemophilic patients with inhibitors: safety, monitoring, and cost effectiveness.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Continuous infusion of recombi ...... oring, and cost effectiveness.
@ast
Continuous infusion of recombi ...... oring, and cost effectiveness.
@en
Continuous infusion of recombi ...... oring, and cost effectiveness.
@nl
type
label
Continuous infusion of recombi ...... oring, and cost effectiveness.
@ast
Continuous infusion of recombi ...... oring, and cost effectiveness.
@en
Continuous infusion of recombi ...... oring, and cost effectiveness.
@nl
prefLabel
Continuous infusion of recombi ...... oring, and cost effectiveness.
@ast
Continuous infusion of recombi ...... oring, and cost effectiveness.
@en
Continuous infusion of recombi ...... oring, and cost effectiveness.
@nl
P356
P1476
Continuous infusion of recombi ...... oring, and cost effectiveness.
@en
P2093
S Schulman
rFVIIa-CI Group
P304
P356
10.1055/S-2000-8462
P577
2000-01-01T00:00:00Z